Alpha-Synucleinopathies Comparison Matrix
Alpha-synucleinopathies are a group of neurodegenerative disorders characterized by the accumulation of abnormal alpha-synuclein protein aggregates in the brain. This comparison matrix covers four major alpha-synucleinopathies: [Parkinson's Disease](/diseases/parkinsons-disease-disease) (PD), Dementia with Lewy Bodies (DLB), Multiple System Atrophy (MSA), and Progressive Supranuclear Palsy (PSP).
Overview
| Feature | Parkinson's Disease | Dementia with Lewy Bodies | Multiple System Atrophy | Progressive Supranuclear Palsy |
|---------|---------------------|--------------------------|-------------------------|------------------------------|
| Year Described | 1817 (James Parkinson) | 1961 (Denong) | 1960 (Menzel) | 1963 (Steele-Richardson-Olszewski) |
| Primary Protein | Alpha-synuclein | Alpha-synuclein | Alpha-synuclein | [Tau](/proteins/tau) (4R) |
| Main Pathology | Lewy bodies | Lewy bodies | Glial cytoplasmic inclusions | NFTs, tufted [astrocytes](/entities/astrocytes) |
| Main Gene | [SNCA](/genes/snca), [LRRK2](/genes/lrrk2), [GBA](/genes/gba) | [SNCA](/genes/snca), [GBA](/genes/gba) | [SNCA](/genes/snca), [COQ2](/genes/coq2) | [MAPT](/genes/mapt) |
Pathway / Mechanism Diagram
...Alpha-Synucleinopathies Comparison Matrix
Alpha-synucleinopathies are a group of neurodegenerative disorders characterized by the accumulation of abnormal alpha-synuclein protein aggregates in the brain. This comparison matrix covers four major alpha-synucleinopathies: [Parkinson's Disease](/diseases/parkinsons-disease-disease) (PD), Dementia with Lewy Bodies (DLB), Multiple System Atrophy (MSA), and Progressive Supranuclear Palsy (PSP).
Overview
| Feature | Parkinson's Disease | Dementia with Lewy Bodies | Multiple System Atrophy | Progressive Supranuclear Palsy |
|---------|---------------------|--------------------------|-------------------------|------------------------------|
| Year Described | 1817 (James Parkinson) | 1961 (Denong) | 1960 (Menzel) | 1963 (Steele-Richardson-Olszewski) |
| Primary Protein | Alpha-synuclein | Alpha-synuclein | Alpha-synuclein | [Tau](/proteins/tau) (4R) |
| Main Pathology | Lewy bodies | Lewy bodies | Glial cytoplasmic inclusions | NFTs, tufted [astrocytes](/entities/astrocytes) |
| Main Gene | [SNCA](/genes/snca), [LRRK2](/genes/lrrk2), [GBA](/genes/gba) | [SNCA](/genes/snca), [GBA](/genes/gba) | [SNCA](/genes/snca), [COQ2](/genes/coq2) | [MAPT](/genes/mapt) |
Pathway / Mechanism Diagram
Mermaid diagram (expand to render)
Clinical Features Comparison
| Feature | Parkinson's Disease | Dementia with Lewy Bodies | Multiple System Atrophy | Progressive Supranuclear Palsy |
|---------|---------------------|--------------------------|-------------------------|------------------------------|
| Core Motor Symptoms | Resting tremor, bradykinesia, rigidity, postural instability | Parkinsonism + hallucinations | Parkinsonism + autonomic failure + cerebellar signs | Vertical gaze palsy, axial rigidity, falls |
| Onset Age (typical) | 60-70 years | 65-80 years | 50-60 years | 60-70 years |
| Disease Duration | 10-20 years | 5-10 years | 5-10 years | 5-10 years |
| Cognitive Decline | Late-stage (PDD) | Early, prominent | Moderate | Early, prominent |
| Hallucinations | Late-stage (drug-induced) | Core feature (recurrent, vivid) | Rare | Rare |
| Autonomic Dysfunction | Mild-moderate (orthostatic hypotension, constipation) | Prominent | Severe (orthostatic hypotension, urinary dysfunction) | Moderate |
| Cerebellar Signs | Rare | Rare | Common (ataxia, nystagmus) | Rare |
| Sleep Disorders | RBD common | RBD common (80%) | RBD common | Night-time behaviors |
| Treatment Response | Good to dopaminergic therapy | Variable, sensitive to antipsychotics | Poor | Poor |
Genetics
| Feature | Parkinson's Disease | Dementia with Lewy Bodies | Multiple System Atrophy | Progressive Supranuclear Palsy |
|---------|---------------------|--------------------------|-------------------------|------------------------------|
| Sporadic Cases | ~90% | ~80% | ~70% | ~95% |
| Familial Cases | ~10% | ~20% | ~30% | ~5% |
| Major Risk Genes | [SNCA](/genes/snca), [LRRK2](/genes/lrrk2), [GBA](/genes/gba), [PARKIN](/genes/parkin), [PINK1](/genes/pink1), [DJ-1](/genes/dj1) | [SNCA](/genes/snca), [GBA](/genes/gba), [APOE](/genes/apoe) | [SNCA](/genes/snca), [COQ2](/genes/coq2), [GBA](/genes/gba) | [MAPT](/genes/mapt), [STX6](/genes/stx6), [MOPB](/genes/mopb) |
| Inheritance Pattern | Mostly complex | Complex or autosomal dominant | Usually sporadic | Usually sporadic |
| Penetrance | Incomplete | Variable | Variable | Low |
Neuropathology
| Feature | Parkinson's Disease | Dementia with Lewy Bodies | Multiple System Atrophy | Progressive Supranuclear Palsy |
|---------|---------------------|--------------------------|-------------------------|------------------------------|
| Key Inclusions | Lewy bodies (neuronal) | Cortical Lewy bodies | Glial cytoplasmic inclusions (GCIs) | NFTs, tufted astrocytes |
| Location | Substantia nigra, [cortex](/brain-regions/cortex) | Cortex, limbic, brainstem | Basal ganglia, cerebellum, olivary nuclei | Brainstem, basal ganglia, cortex |
| Cell Loss | Substantia nigra dopaminergic | Variable | Multi-system atrophy | Substantia nigra, globus pallidus |
| Neurotransmitter Affected | Dopamine | Dopamine, [acetylcholine](/entities/acetylcholine) | Multiple (dopamine, norepinephrine) | Dopamine, GABA |
Treatment Approaches
| Feature | Parkinson's Disease | Dementia with Lewy Bodies | Multiple System Atrophy | Progressive Supranuclear Palsy |
|---------|---------------------|--------------------------|-------------------------|------------------------------|
| Motor Symptoms | Levodopa, dopamine agonists, MAO-B inhibitors | Levodopa (variable response) | Levodopa (often poor response) | Limited response |
| Cognitive Symptoms | [Cholinesterase inhibitors](/entities/cholinesterase-inhibitors) | Cholinesterase inhibitors (first-line) | No approved therapy | Limited options |
| Autonomic | Midodrine, fludrocortisone | Supportive care | Supportive care | Limited options |
| Disease-Modifying | None approved | None approved | None approved | None approved |
Biomarkers
| Feature | Parkinson's Disease | Dementia with Lewy Bodies | Multiple System Atrophy | Progressive Supranuclear Palsy |
|---------|---------------------|--------------------------|-------------------------|------------------------------|
| Imaging | DaTscan (reduced dopamine uptake) | Reduced uptake, occipital hypometabolism | Reduced uptake + autonomic testing | MRI: midbrain atrophy |
| CSF | Alpha-synuclein (reduced) | Alpha-synuclein, tau | Alpha-synuclein (reduced) | Tau elevated |
| Sleep | RBD on polysomnography | RBD (core feature) | RBD common | Sleep fragmentation |
Key Differential Features
| Feature | Parkinson's Disease | Dementia with Lewy Bodies | Multiple System Atrophy | Progressive Supranuclear Palsy |
|---------|---------------------|--------------------------|-------------------------|------------------------------|
| Hallmark Sign | Resting tremor | Visual hallucinations | Autonomic failure + cerebellar | Vertical supranuclear gaze palsy |
| Disease Course | Slow progression | Fluctuating course | Rapid progression | Rapid progression |
| Response to Levodopa | Good | Variable | Usually poor | Poor |
Cross-Reference Links
- [Alpha-Synucleinopathies](/diseases/alpha-synucleinopathies)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Dementia with Lewy Bodies](/diseases/dementia-lewy-bodies)
- [Multiple System Atrophy](/diseases/multiple-system-atrophy)
- [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
- [Alpha-Synuclein](/proteins/alpha-synuclein)
- [Synucleinopathies Biomarkers](/biomarkers/synucleinopathies-biomarkers)
See Also
- [Parkinson's Disease](/diseases/parkinsons-disease-disease)
- [SNCA](/genes/snca)
- [LRRK2](/genes/lrrk2)
- [GBA](/genes/gba)
- [COQ2](/genes/coq2)
- [MAPT](/genes/mapt)
- [PARKIN](/genes/parkin)
- [PINK1](/genes/pink1)
- [DJ-1](/genes/dj1)
- [APOE](/genes/apoe)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
[Unknown, Beyond alpha-synuclein therapy: What is next? (2023)](https://doi.org/10.1016/j.jns.2023.122678)
[Unknown, DLB consensus criteria 2017 (2017)](https://doi.org/10.1016/j.jalz.2017.04.012)
[Unknown, MSA consensus criteria 2008 (2008)](https://doi.org/10.1212/01.wnl.0000324625.00404.15)
[Unknown, PSP: clinical features and diagnosis (2022)](https://doi.org/10.1016/j.jns.2022.120399)
[Unknown, Genetic forms of Parkinson's disease (n.d.)](https://pubmed.ncbi.nlm.nih.gov/34519153/)
[Unknown, Alpha-synucleinopathies: pathophysiology and clinical phenotype (n.d.)](https://doi.org/10.1002/mus.27256)